文献速递男科与性医学

为医疗保险受益人置入可膨胀阴茎假体治疗勃起功能障碍的机构所实现的下游收入

Downstream Revenue Realized by Facilities Placing Inflatable Penile Prosthesis in Medicare Beneficiaries to Treat Erectile Dysfunction.
PubMed 文献 · Urology · 2024-04-26

基于100%医疗保险标准分析文件的回顾性索赔分析,比较2016年1月1日至2021年12月31日期间接受可膨胀阴茎假体(IPP)治疗的勃起功能障碍(ED)男性与倾向匹配的无ED男性在5年内的下游收入。IPP队列5年累计收入均值34571美元(SD=50234),无ED组均值3189美元(SD=11527),IPP队列显著更高。

要点

  • IPP队列5年累计收入均值34571美元(SD=50234),无ED组均值3189美元(SD=11527)。
  • 按诊断分层收入差:循环系统疾病10258美元、糖尿病2646美元、泌尿科2013美元、前列腺癌1043美元。
  • IPP患者至少1次就诊比例:循环系统55.0% vs 7.8%,泌尿科46.7% vs 16.8%,糖尿病19.3% vs 3.6%,前列腺癌19.0% vs 3.0%。

核心结论

  • 接受IPP的ED男性在5年内为医疗系统产生的收入显著高于无ED男性,约为后者的近10倍,且不含IPP手术初始费用。

研究设计与样本

  • 回顾性索赔分析,使用100%医疗保险标准分析文件,纳入2016年1月1日至2021年12月31日在医院门诊接受IPP置入(CPT 54405)且年龄≥65岁的ED男性,要求索引IPP前12个月及IPP出院后5年持续参加医疗保险A和B部分,并与特征相当的无ED男性进行倾向匹配比较。
  • 匹配后ED接受IPP组2905人,无ED组7462人。

主要发现

  • IPP队列5年累计收入均值34571美元(SD=50234),无ED组均值3189美元(SD=11527),IPP队列显著更高。
  • 按诊断类型分层,收入差分别为循环系统疾病10258美元、糖尿病2646美元、泌尿科2013美元、前列腺癌1043美元。
  • 5年随访期间至少1次因这些疾病就诊的比例:循环系统55.0% vs 7.8%,泌尿科46.7% vs 16.8%,糖尿病19.3% vs 3.6%,前列腺癌19.0% vs 3.0%,IPP患者均显著更多。

临床怎么用

  • 作者认为这些发现强调晚期ED项目的财务影响,以改善这些患者获得必要医疗的机会。
  • 作者认为医疗机构可利用这些见解有效分配资源,为ED男性提供关键医疗服务。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To quantify the incremental downstream revenue generated from subsequent treatment of men who received an inflatable penile prosthesis (IPP) to treat erectile dysfunction (ED), compared to men without ED. METHODS: The 100% Medicare Standard Analytic Files were used to conduct a retrospective claims analysis of the 5-year revenue generated by patients receiving IPP to treat their ED, compared to a propensity-matched cohort of men without ED. Men aged 65 years or older with ED who underwent IPP implantation (Current Procedural Terminology 54405) in a hospital outpatient setting between January 1, 2016 and December 31, 2021, and who had continuous Medicare Parts A and B enrollment for 12 months pre-index IPP and 5 years post-index IPP discharge date were included in the study. Men without ED but with comparable characteristics were identified and used as a comparator group. Revenue received by hospitals from Medicare was defined as the sum of payments for patient services, other payor-paid amounts, patient deductibles, copayments, and coinsurance. Revenue was inflated to 2022 US dollars. The mean values and their corresponding standard deviations (SD) are reported. RESULTS: After matching, there were 2905 men with ED who received an IPP and 7462 men without ED. The IPP cohort showed a significantly higher 5-year cumulative revenue (mean=$34,571 [SD=$50,234]) compared to the men without ED (mean=$3189 [SD=$11,527]). When stratified by diagnosis type, the differences in revenue were $10,258 for circulatory disease, $2646 for diabetes, $2013 for urology, and $1043 for prostate cancer. Significantly more IPP patients had at least 1 health encounter for these conditions over the 5-year follow-up period than their matched controls (55.0% vs 7.8% for circulatory, 46.7% vs 16.8% for urology, 19.3% vs 3.6% for diabetes, and 19.0% vs 3.0% for prostate cancer). CONCLUSION: Men with ED who received IPP generated substantially higher revenue for the healthcare system over a 5-year period, nearly 10 times as much, compared to men without ED, excluding the initial cost of the IPP procedure. The presence of ED, coupled with IPP usage, is associated with significantly increased healthcare revenue across a range of medical conditions compared to men without ED. These findings emphasize the financial implications for advanced ED programs to improve access to necessary care for these patients. Healthcare facilities may leverage these insights to effectively allocate resources to deliver critical healthcare to men with ED.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Sun A, Williams AO, Rojanasarot S, et al. Downstream Revenue Realized by Facilities Placing Inflatable Penile Prosthesis in Medicare Beneficiaries to Treat Erectile Dysfunction. Urology. 2024. PMID: 38677374. doi:10.1016/j.urology.2024.04.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。